可乐逆转维帕他韦与奥美拉唑药物相互作用研究
该开放标签随机交叉试验在11名健康成人中评估可乐对维帕他韦与奥美拉唑相互作用的影响。索磷布韦/维帕他韦联用奥美拉唑使维帕他韦暴露降低26.7%,而联用可乐可补偿该相互作用并提高维帕他韦暴露。因此可乐可用于克服维帕他韦与奥美拉唑之间的药物相互作用。
要点
- 索磷布韦/维帕他韦联用奥美拉唑使维帕他韦AUC0-inf的GMR降至73.3%。
- 联用可乐后维帕他韦AUC0-inf的GMR升至161.6%,可补偿奥美拉唑影响。
- 可乐可用于管理维帕他韦与奥美拉唑的相互作用。
核心结论
- 可乐可补偿奥美拉唑对维帕他韦暴露的降低作用,用于克服两者药物相互作用。
研究设计与样本
- 开放标签、随机、交叉试验,纳入11名健康成人。
- 单剂索磷布韦/维帕他韦400/100 mg单用为参照,或联用奥美拉唑40 mg每日一次用水送服为干预I,或奥美拉唑40 mg联用250 mL可乐为干预II。
主要发现
- 索磷布韦/维帕他韦联用奥美拉唑较参照使维帕他韦暴露降低26.7%。
- 维帕他韦AUC0-inf的GMR(90%CI)为73.3%(55.6-96.8),Cmax的GMR为69.1%(52.3-91.2)。
- 索磷布韦/维帕他韦联用可乐后维帕他韦AUC0-inf的GMR(90%CI)为161.6%(122.4-213.3),Cmax的GMR为143.9%(109.0-190.0)。
临床怎么用
- 对需联用奥美拉唑的患者,可考虑用可乐送服索磷布韦/维帕他韦以补偿维帕他韦暴露下降。
局限性
- 研究仅纳入11名健康成人,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to evaluate the effect of the acid beverage Coca-Cola on the pharmacokinetics of velpatasvir (VEL) when given with omeprazole. This was an open-label, randomized, crossover trial in 11 healthy adults. A single dose of sofosbuvir/velpatasvir (SOF/VEL) 400/100 mg was administered alone (reference) or with omeprazole 40 mg once daily with water (intervention I); in the intervention II arm, omeprazole 40 mg was combined with 250 mL of Coca-Cola. Geometric mean ratios (GMRs) were calculated for VEL area under the concentration-time curve from zero to infinity (AUC0-inf ) and maximum plasma concentration (Cmax ). VEL exposure was reduced by 26.7% when SOF/VEL was coadministered with omeprazole vs. reference: GMRs (90% confidence interval (CI)) were 73.3% (55.6-96.8) and 69.1% (52.3-91.2) for AUC0-inf and Cmax , respectively. Intake of SOF/VEL with Coca-Cola compensated for the interaction with omeprazole and resulted in a higher VEL exposure. GMRs (90% CI) were 161.6% (122.4-213.3) for AUC0-inf and 143.9% (109.0-190.0) for Cmax . Therefore, Coca-Cola can be used to overcome the drug-drug interaction between VEL and omeprazole.
引用
- van Seyen M, Colbers A, Abbink EJ, et al. Concomitant Intake of Coca-Cola to Manage the Drug-Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers. Clin Pharmacol Ther. 2019. PMID: 31313296. doi:10.1002/cpt.1569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。